FREDERICK, Md.–(BUSINESS WIRE)—Royer Biomedical Inc. (RBI) was awarded a US patent covering the core technologies of its proprietary AppliGel dissolvable non-immunogenic Polymer Drug Delivery System Platform. The US Patent and Trademark Office allowed 53 claims broadly covering composition of matter, methods, commercial kits, and formulations. AppliGel Drug Delivery System Platform received pre-IND pathway concurrence earlier this year. The Company is nearing completion of required animal testing in anticipation of submission to the FDA for an IND to initiate Phase I/II human testing in Q2 of 2012.
“This patent represents years of innovation and development” said William Wolf MD, RBI’s President and CEO. “We are proud that the USPTO has allowed such a broad set of claims, and we look forward to gaining final approval for topical, injectable, and implantable drug delivery applications for antibiotics, chemotherapeutics, and analgesics to address Diabetic Foot Ulcers (DFU), Oncology, and other conditions requiring sustained medication in a dissolvable platform without immunogenic reaction or the need for removal. Our AppliGel polymer platform’s shelf stability, ease of application, and ability to deliver pharmaceuticals without significant adverse effects has been well-demonstrated in the veterinary world, and the prospect of collaborating with Johns Hopkins University Hospital and Georgetown University Hospital to improve patient outcomes in Cancer and Diabetes is truly exciting.”